347 related articles for article (PubMed ID: 30982556)
21. Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine.
Luxembourg A; Brown D; Bouchard C; Giuliano AR; Iversen OE; Joura EA; Penny ME; Restrepo JA; Romaguera J; Maansson R; Moeller E; Ritter M; Chen J
Hum Vaccin Immunother; 2015; 11(6):1313-22. PubMed ID: 25912208
[TBL] [Abstract][Full Text] [Related]
22. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
23. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
FUTURE II Study Group
N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
[TBL] [Abstract][Full Text] [Related]
25. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
26. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
[TBL] [Abstract][Full Text] [Related]
27. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.
Luxembourg A; Kjaer SK; Nygard M; Ellison MC; Group T; Marshall JB; Radley D; Saah A
Contemp Clin Trials; 2017 Jan; 52():54-61. PubMed ID: 27777126
[TBL] [Abstract][Full Text] [Related]
28. Spotlight on the 9-valent HPV vaccine.
Lopalco PL
Drug Des Devel Ther; 2017; 11():35-44. PubMed ID: 28053505
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
[TBL] [Abstract][Full Text] [Related]
30. The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age.
Zhao C; Zhao Y; Li J; Li M; Su Y; Mi X; La Tu SY; Shen D; Ren L; Li Y; Wang L; Wei L
Hum Vaccin Immunother; 2022 Nov; 18(5):2052700. PubMed ID: 35358015
[TBL] [Abstract][Full Text] [Related]
31. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
32. A controlled trial of a human papillomavirus type 16 vaccine.
Koutsky LA; Ault KA; Wheeler CM; Brown DR; Barr E; Alvarez FB; Chiacchierini LM; Jansen KU;
N Engl J Med; 2002 Nov; 347(21):1645-51. PubMed ID: 12444178
[TBL] [Abstract][Full Text] [Related]
33. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
Garland SM; Paavonen J; Jaisamrarn U; Naud P; Salmerón J; Chow SN; Apter D; Castellsagué X; Teixeira JC; Skinner SR; Hedrick J; Limson G; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Germar MJ; Peters K; Del Rosario-Raymundo MR; Catteau G; Descamps D; Struyf F; Lehtinen M; Dubin G;
Int J Cancer; 2016 Dec; 139(12):2812-2826. PubMed ID: 27541373
[TBL] [Abstract][Full Text] [Related]
34. Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial.
Ferris DG; Brown DR; Giuliano AR; Myers E; Joura EA; Garland SM; Kjaer SK; Perez G; Saah A; Luxembourg A; Velicer C
Papillomavirus Res; 2020 Dec; 10():100202. PubMed ID: 32464334
[TBL] [Abstract][Full Text] [Related]
35. Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study.
Rahman S; Pierce Campbell CM; Rollison DE; Wang W; Waterboer T; Michel A; Pawlita M; Villa LL; Lazcano Ponce E; Borenstein AR; Giuliano AR
PLoS One; 2016; 11(11):e0167173. PubMed ID: 27902759
[TBL] [Abstract][Full Text] [Related]
36. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.
Palefsky JM; Giuliano AR; Goldstone S; Moreira ED; Aranda C; Jessen H; Hillman R; Ferris D; Coutlee F; Stoler MH; Marshall JB; Radley D; Vuocolo S; Haupt RM; Guris D; Garner EI
N Engl J Med; 2011 Oct; 365(17):1576-85. PubMed ID: 22029979
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and safety of the 9-valent HPV vaccine in men.
Castellsagué X; Giuliano AR; Goldstone S; Guevara A; Mogensen O; Palefsky JM; Group T; Shields C; Liu K; Maansson R; Luxembourg A; Kaplan SS
Vaccine; 2015 Nov; 33(48):6892-901. PubMed ID: 26144901
[TBL] [Abstract][Full Text] [Related]
38. 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.
Pitisuttithum P; Velicer C; Luxembourg A
Expert Rev Vaccines; 2015; 14(11):1405-19. PubMed ID: 26366475
[TBL] [Abstract][Full Text] [Related]
39. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.
Lang Kuhs KA; Porras C; Schiller JT; Rodriguez AC; Schiffman M; Gonzalez P; Wacholder S; Ghosh A; Li Y; Lowy DR; Kreimer AR; Poncelet S; Schussler J; Quint W; van Doorn LJ; Sherman ME; Sidawy M; Herrero R; Hildesheim A; Safaeian M;
Am J Epidemiol; 2014 Sep; 180(6):599-607. PubMed ID: 25139208
[TBL] [Abstract][Full Text] [Related]
40. Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types.
Ryser M; Berlaimont V; Karkada N; Mihalyi A; Rappuoli R; van der Most R
Expert Rev Vaccines; 2019 Mar; 18(3):309-322. PubMed ID: 30739514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]